In the BioHarmony Drug Report Database

"Preview" Icon

Dupilumab

Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha. In addition, it is known to target Interleukin-4 receptor subunit alpha.

 

Trade Name

 

Dupixent
 

Common Name

 

dupilumab
 

ChEMBL ID

 

CHEMBL2108675
 

Indication

 

atopic dermatitis
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Dupilumab structure rendering